13 active not recruiting. 13 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Active not recruiting 13 |
| Phase 2 | 7 | Active not recruiting 7 |
Follow Blood Coagulation Disorders: new trials by email Literature Review of Blood Coagulation Disorders trials Research Report on Blood Coagulation Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bioequivalence Study of SKI-O-703 in Healthy Adults Under Fed Conditions SKI-O-703 API in Capsules, SKI-O-703 Formulated Granules in Capsules - Bioequivalence Study in Healthy Subjects, Immune Thrombocytopenia (ITP) | Phase 1 | Active not recruiting | Oscotec Inc. | 48 | 2026-07-10 | 2026-09-01 |
| A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms INCA033989, Ruxolitinib - Myeloproliferative Neoplasms | Phase 1 | Active not recruiting | Incyte Corporation | 160 | 2023-09-25 | 2026-08-10 |
| A Trial of the Safety and Efficacy of Single-Dose Administration of ANB-010 in Subjects With Hemophilia A ANB-010, dose 1, ANB-010, dose 2, ANB-010, dose 3 - Hemophilia A | Phase 1 / Phase 2 | Active not recruiting | Biocad | 50 | 2023-07-26 | 2025-04-24 |
| To Evaluate the Safety and Efficacy of GS1191-0445 Injection in the Treatment of Severe Hemophilia A GS1191-0445 injection - Severe Hemophilia A | Phase 1 / Phase 2 | Active not recruiting | Gritgen Therapeutics Co., Ltd. | 7 | 2023-07-10 | 2026-05-06 |
| Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm Peptide-based vaccine, Poly ICLC - Myelofibrosis, Essential Thrombocythemia | Phase 1 | Active not recruiting | Marina Kremyanskaya | 7 | 2023-04-04 | 2026-09-28 |
| A Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Glanzmann Thrombasthenia HMB-001 - Glanzmann Thrombasthenia | Phase 1 / Phase 2 | Active not recruiting | Hemab ApS | 57 | 2022-12-13 | 2026-09-25 |
| Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms INCB057643, Ruxolitinib - Myelofibrosis, Myelodysplastic Syndrome | Phase 1 | Active not recruiting | Incyte Corporation | 140 | 2021-02-23 | 2026-04-01 |
| Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia A Auto CD34+PBSC, transduced with a lentiviral vector encoding the B domain deleted from of human coagulation factor VIII - Hemophilia A | Phase 1 | Active not recruiting | Medical College of Wisconsin | 5 | 2020-04-29 | 2026-07-13 |
| A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm Navitoclax, Ruxolitinib, Celecoxib - Myeloproliferative Neoplasm | Phase 1 | Active not recruiting | AbbVie | 85 | 2019-11-08 | 2025-02-14 |
| Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Azacitidine, Pevonedistat, Venetoclax - Acute Myeloid Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 40 | 2019-02-27 | 2026-07-16 |
| Gene Therapy for Haemophilia A. AAV2/8-HLP-FVIII-V3 - Hemophilia A | Phase 1 / Phase 2 | Active not recruiting | University College, London | 14 | 2017-06-14 | 2025-03-05 |
| Long Term Safety Follow up of Haematopoietic Stem Cell Gene Therapy for the Wiskott Aldrich Syndrome Autologous CD34+ cells transduced with WASP lentiviral vector - Wiskott-Aldrich Syndrome | Phase 1 / Phase 2 | Active not recruiting | Genethon | 10 | 2014-09-01 | 2021-06-03 |
| Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B AskBio009 - Hemophilia B | Phase 1 / Phase 2 | Active not recruiting | Baxalta now part of Shire | 30 | 2013-02-11 | 2026-03-20 |
Primary Myelofibrosis (5) · Thrombocythemia, Essential (5) · Hemophilia A (4) · Myeloproliferative Disorders (4) · Leukemia, Myelomonocytic, Chronic (2) · Myelodysplastic Syndromes (2) · Polycythemia Vera (2) · Arthritis, Rheumatoid (1) · Hemophilia B (1) · Hypereosinophilic Syndrome (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (1) · Leukemia, Neutrophilic, Chronic (1) · Neoplasms (1) · Purpura, Thrombocytopenic, Idiopathic (1)
Hematologic Diseases (13) · Hemic and Lymphatic Diseases (13) · Hemorrhagic Disorders (13) · Blood Coagulation Disorders, Inherited (7) · Blood Platelet Disorders (7) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7) · Genetic Diseases, Inborn (7) · Bone Marrow Diseases (5) · Coagulation Protein Disorders (5) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Thrombocytosis (4) · Disease Attributes (3) · Bone Marrow Neoplasms (2)
ruxolitinib (3) · Azacitidine (1) · BAX 335 (1) · Capsules (1) · Celecoxib (1) · INCB057643 (1) · navitoclax (1) · pevonedistat (1) · poly ICLC (1) · venetoclax (1)
Incyte Corporation (2) · AbbVie (1) · Baxalta now part of Shire (1) · Biocad (1) · Genethon (1) · Gritgen Therapeutics Co., Ltd. (1) · Hemab ApS (1) · M.D. Anderson Cancer Center (1) · Marina Kremyanskaya (1) · Medical College of Wisconsin (1) · Oscotec Inc. (1) · University College, London (1)
United States (8) · United Kingdom (6) · France (4) · Italy (4) · Japan (3) · Spain (3) · Belgium (2) · Canada (2) · China (2) · Germany (2) · Australia (1) · Bulgaria (1) · Croatia (1) · Denmark (1) · Finland (1)
Arina V Zinkina-Orikhan, PhD (1) · Camelia Iancu-Rubin, PhD (1) · Marina Kremyanskaya, MD, PhD (1) · Mary Eapen, MD (1) · Nicholas Short (1) · Nina Bhardwaj, MD, PhD (1) · Pratima Chowdary, MD (1)
PMID 30003118, PMID 33067633, PMID 35075289, PMID 37422688
2016 (1), 2023 (1)